Published in Clin Exp Immunol on June 01, 2006
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer (2012) 1.06
Genetic engineering of T cells for adoptive immunotherapy. Immunol Res (2008) 1.05
Effector T lymphocytes in well-nourished and malnourished infected children. Clin Exp Immunol (2007) 1.04
Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer (2013) 0.88
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. Cytotherapy (2007) 0.84
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
The B7-CD28 superfamily. Nat Rev Immunol (2002) 7.24
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther (1996) 7.12
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol (2002) 5.49
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol (2003) 5.01
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood (2004) 3.05
Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J Immunol (1996) 2.76
Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med (1996) 2.73
Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A (1995) 2.68
Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol (2004) 2.49
Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol (2000) 2.17
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol (1998) 1.96
Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol (2002) 1.92
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood (2002) 1.89
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res (1995) 1.76
Human virus-specific CD8+ CTL clones revert from CD45ROhigh to CD45RAhigh in vivo: CD45RAhighCD8+ T cells comprise both naive and memory cells. J Immunol (1999) 1.71
Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med (2003) 1.55
Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer (2001) 1.46
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood (2004) 1.43
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother (2005) 1.41
Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther (2004) 1.41
Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol (2002) 1.31
Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood (2000) 1.15
Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood (2002) 1.13
Functional expression of chimeric receptor genes in human T cells. J Immunol Methods (2001) 1.12
Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med (1995) 1.07
CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.06
Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood (2001) 1.04
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol (2005) 1.01
Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin Cancer Res (1997) 0.89
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med (1996) 4.42
The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 2.55
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia (2006) 2.35
Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia (1996) 1.96
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther (2005) 1.70
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol (1999) 1.58
Understanding the cancer stem cell. Br J Cancer (2010) 1.42
Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols. Hum Mol Genet (1995) 1.14
Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klin Padiatr (1997) 1.12
Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin Orthop Relat Res (1999) 1.09
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer (2012) 1.06
Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol (2000) 1.03
Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia (2010) 0.99
Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). Natl Cancer Inst Monogr (1981) 0.98
High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol (2003) 0.98
Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer (2001) 0.97
Osteosarcoma after allogeneic bone marrow transplantation. A report of four cases from the Cooperative Osteosarcoma Study Group (COSS). Bone Marrow Transplant (2003) 0.94
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia (2011) 0.94
Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant (2004) 0.94
Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients. Ann Oncol (2002) 0.93
Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. Eur J Pediatr (2001) 0.93
Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J Pediatr (1999) 0.92
Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia (2011) 0.92
Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant (2005) 0.90
Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice. Blood (1996) 0.89
Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer (2013) 0.88
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther (2005) 0.88
Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol (2004) 0.86
Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia (2012) 0.86
PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. Br J Cancer (2005) 0.86
Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML. Leukemia (2011) 0.85
Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. Bone Marrow Transplant (2007) 0.85
Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol (2002) 0.85
Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med Pediatr Oncol (2000) 0.85
Expression of AC133 and CD117 on candidate normal stem cell populations in childhood B-cell precursor acute lymphoblastic leukaemia. Br J Haematol (1999) 0.84
Adoptive cellular immunotherapy with CD19-specific T cells. Klin Padiatr (2005) 0.84
Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. Bone Marrow Transplant (2008) 0.84
Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. J Cancer Res Clin Oncol (2007) 0.82
Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. Pediatr Blood Cancer (2013) 0.82
Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Transplant (2013) 0.81
Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin Padiatr (2006) 0.81
Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monogr (1981) 0.80
Chemical and immunological characteristics of four different L-asparaginase preparations. Eur J Haematol (1989) 0.80
Farber's disease without central nervous system involvement: bone-marrow transplantation provides a promising new approach. Ann Rheum Dis (2006) 0.80
Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia (2010) 0.80
Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11). Br J Haematol (2006) 0.80
[Procedure guidelines for whole-body 18F-FDG PET and PET/CT in children with malignant diseases]. Nuklearmedizin (2010) 0.79
Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells. Leukemia (2006) 0.79
Catheter-associated aspergillosis of the chest wall following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis (2010) 0.78
PET surveillance of patients with Ewing sarcomas of the trunk: Must the lower legs be included? Nuklearmedizin (2010) 0.78
Efficacy and kinetics of bone marrow processing and enrichment of haematopoietic progenitor cells (HPC) by a large-volume apheresis procedure. Bone Marrow Transplant (1997) 0.78
Increased DNA-repair capacity and the modulation of 2 proteins in and metallothionein overexpressing Chinese hamster cell line. Mutat Res (1994) 0.78
Gene expression changes in cancellous bone of type 2 diabetics: a biomolecular basis for diabetic bone disease. Langenbecks Arch Surg (2014) 0.78
Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy--a combined analysis of 713 type 2 diabetic patients. Diabetes Obes Metab (2013) 0.77
Effect of radiation on Ewing tumour subpopulations characterized on a single-cell level: intracellular cytokine, immunophenotypic, DNA and apoptotic profile. Int J Radiat Biol (2003) 0.77
Cell heterogeneity and subpopulations in solid tumors characterized by simultaneous immunophenotyping and DNA content analysis. Cytometry (2000) 0.77
Cerebral toxoplasmosis in an adolescent post allogeneic hematopoietic stem cell transplantation: successful outcome by antiprotozoal chemotherapy and CD4+ T-lymphocyte recovery. Transpl Infect Dis (2015) 0.77
Bordetella pertussis respiratory infection following hematopoietic stem cell transplantation: time for universal vaccination? Bone Marrow Transplant (2006) 0.76
Elimination of l-asparaginase in children treated for acute lymphoblastic leukemia. Dev Pharmacol Ther (1989) 0.76
[Transient myeloproliferation and acute myeloid leukemia in infants with Down's syndrome]. Klin Padiatr (1990) 0.76
Metastatic neuroblastoma demonstrated by whole-body PET-CT using 11C-HED. Nuklearmedizin (2005) 0.75
Important aspects of cost-effectiveness analysis in febrile neutropenia. Infection (2000) 0.75
Combination chemotherapy (T-6) in the multidisciplinary treatment of Ewing's sarcoma. Natl Cancer Inst Monogr (1981) 0.75
Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood--follow up after 9 years. Coall Study Group. Eur J Pediatr (1996) 0.75
Prognostic significance of Auer rods in childhood acute myelogenous leukemia: results of the studies AML-BFM-78 and -83. Med Pediatr Oncol (1989) 0.75
Heterogeneity of radiation induced apoptosis in Ewing Tumor cell lines characterized on a single cell level. Apoptosis (2005) 0.75
Time- and dose-dependent changes of intracellular cytokine and cytokine receptor profile of Ewing tumour subpopulations under the influence of ionizing radiation. Int J Radiat Biol (2003) 0.75
[Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study]. Klin Padiatr (2002) 0.75
Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly. Klin Padiatr (2001) 0.75
The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy. J Neurooncol (1983) 0.75
Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations. Haematol Blood Transfus (1990) 0.75
Intravenous hyperimmunoglobulin to prevent varicella-zoster infection. Pediatr Infect Dis J (1987) 0.75
Early intensification therapy in high-risk childhood acute lymphocytic leukemia: lack of benefit from high-dose methotrexate. Haematol Blood Transfus (1987) 0.75
[Flow cytometric characterization of maturation processes and primitive stem cell population in pre-B-cell ALL in childhood]. Klin Padiatr (1996) 0.75